drugset / Trial / NCT05085561
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
Timeline
- Start
- 2022-03-17
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | REC-994 | Unknown | 200 mg | — |
| Comparator | REC-994 | Unknown | 400 mg | — |